ArticleThe American journal of gastroenterology2025
Gastric (Foveolar)-Type Dysplasia in Barrett's Esophagus: A Clinical, Molecular, and Long-Term Outcome Study.
Article in The American journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThe aim of this long-term progression study was to evaluate the clinical and pathologic features of gastric type dysplasia in Barrett's esophagus (BE).
methodsBaseline biopsies from 208 patients with BE from the Seattle prospective cohort were evaluated for the type (gastric or intestinal) and grade of dysplasia. Twenty-seven patients progressed to cancer and 181 did not over the long-term follow-up period. Patients with gastric or intestinal dysplasia were compared with each other regarding their flow cytometric DNA content abnormalities and progression rates to cancer.
resultsOf the 59 patients with dysplasia at baseline, 12 (20%) had gastric-type dysplasia only, 24 (41%) had mixed gastric- and intestinal-type dysplasia, and 23 (39%) had intestinal-type dysplasia only. Patients with any gastric-type dysplasia component (alone or mixed with intestinal-type dysplasia) showed a significantly higher rate of high-grade dysplasia (72% vs 23%, P < 0.001) at baseline and cancer development (47% vs 22%, P = 0.05), and a significantly shorter time frame to cancer development (32 vs 64 months, P = 0.008), as well as a longer BE segment length ( P = 0.05), and higher rate of aneuploidy ( P = 0.04), compared with patients with pure intestinal dysplasia. By multivariable analysis, gastric-type dysplasia showed a higher hazard ratio of progression to cancer compared with patients with intestinal-type dysplasia. DISCUSSION: Gastric-type dysplasia is common in BE. Our study suggests that this type of dysplasia may represent a more aggressive form of neoplastic precursor than conventional intestinal-type dysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.